Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 5Recurrence 2Neoplasms 2Carcinoma, Merkel Cell 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Pharmacokinetics 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Advanced Triple Negative Breast Cancer 1

Interventions

Sorafenib 3vandetanib 2alectinib 2Sodium 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Bevacizumab 2tremelimumab 1temsirolimus 1ponatinib 1perflutren 1pembrolizumab 1methyl N-acetylsibirosaminide 1lenvatinib 1gallium 68 PSMA-11 1fosbretabulin 1durvalumab 1combretastatin 1cobimetinib 1cabozantinib 1X-Rays 1Valproic Acid 1Thyroxine 1Technetium Tc 99m Sestamibi 1Sirolimus 1Radiofrequency Ablation 1Presenilin-1 1Paclitaxel 1PLX8394 1Lubricant Eye Drops 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Thyroid Neoplasms × ALT-803 × Clear all
NCT03127098 2024-08-06

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NantCell, Inc.

Phase 1/2 Terminated
3 enrolled 6 charts
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡